Skip to main content
Figure 1 | Allergy, Asthma & Clinical Immunology

Figure 1

From: Efficacy and onset of action of mometasone furoate/formoterol and fluticasone propionate/salmeterol combination treatment in subjects with persistent asthma

Figure 1

Study Design*. BID = twice daily; DPI = dry powder inhaler; FP/S = fluticasone propionate/salmeterol; MDI = metered-dose inhaler; MF = mometasone furoate; MF/F = mometasone furoate/formoterol. *Doses were delivered via 2 actuations of an MDI (MF 100 μg or MF/F 100/5 μg) or 1 actuation of a DPI (FP/S 250/50 μg) BID. †In the MF/F-MDI 200/10 μg BID treatment group, 42% of subjects discontinued. ‡In the FP/S-DPI 250/50 μg BID treatment group, 41% of subjects discontinued.

Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us